Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib + Carboplatin/Gemcitabine/Pembrolizumab in Advanced Squamous NSCLC
NCT04216316Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of berzosertib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Dose-Limiting Toxicity at cycle 1, Recommended Phase 2 Dose at cycle 1 and 1 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04216316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216316.